Increased endothelin-1 vasoconstriction in mesenteric resistance arteries after superior mesenteric ischaemia-reperfusion

Br J Pharmacol. 2012 Feb;165(4):937-50. doi: 10.1111/j.1476-5381.2011.01617.x.

Abstract

Background and purpose: Endothelin-1 (ET-1) plays an important role in the maintenance of vascular tone. We aimed to evaluate the influence of superior mesenteric artery (SMA) ischaemia-reperfusion (I/R) on mesenteric resistance artery vasomotor function and the mechanism involved in the changes in vascular responses to ET-1.

Experimental approach: SMA from male Sprague-Dawley rats was occluded (90 min) and following reperfusion (24h), mesenteric resistance arteries were dissected. Vascular reactivity was studied using wire myography. Protein and mRNA expression, superoxide anion (O(2) (•-) ) production and ET-1 plasma concentration were evaluated by immunofluorescence, real-time quantitative PCR, ethidium fluorescence and elisa, respectively.

Key results: I/R increased ET-1 plasma concentration, ET-1-mediated vasoconstriction and ET(B) mRNA expression, and down-regulated ET(A) mRNA expression. Immunofluorescence confirmed mRNA results and revealed an increase in ET(B) receptors in the mesenteric resistance artery media layer after I/R. Therefore, the ET(B) receptor agonist sarafotoxin-6 induced a contraction that was inhibited by the ET(B) receptor antagonist BQ788 only in vessels, with and without endothelium, from I/R rats. Furthermore, BQ788 potentiated ET-1 vasoconstriction only in sham rats. Endothelium removal in rings from I/R rats unmasked the inhibition of ET-1 vasoconstriction by BQ788. Endothelium removal, N(ω) -nitro-L-arginine methyl ester and superoxide dismutase abolished the differences in ET-1 vasoconstriction between sham and I/R rats. We also found that I/R down-regulates endothelial NOS mRNA expression and concomitantly enhanced O(2) (•-) production by increasing NADPH oxidase 1 (NOX-1) and p(47phox) mRNA.

Conclusions and implications: Mesenteric I/R potentiated the ET-1-mediated vasoconstriction by a mechanism that involves up-regulation of muscular ET(B) receptors and decrease in NO bioavailability.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acetylcholine / pharmacology
  • Animals
  • Cyclooxygenase Inhibitors / pharmacology
  • Endothelin-1 / blood
  • Endothelin-1 / physiology*
  • Free Radical Scavengers / pharmacology
  • In Vitro Techniques
  • Indomethacin / pharmacology
  • Ischemia / physiopathology*
  • Male
  • Mesenteric Arteries / physiology*
  • Myocytes, Smooth Muscle / physiology
  • NG-Nitroarginine Methyl Ester / pharmacology
  • Nitric Oxide / physiology
  • Nitric Oxide Synthase Type III / antagonists & inhibitors
  • Nitric Oxide Synthase Type III / genetics
  • RNA, Messenger / metabolism
  • Rats
  • Rats, Sprague-Dawley
  • Receptor, Endothelin A / physiology
  • Receptor, Endothelin B / physiology
  • Reperfusion*
  • Superoxide Dismutase / pharmacology
  • Superoxides / metabolism
  • Vasoconstriction / physiology*

Substances

  • Cyclooxygenase Inhibitors
  • Endothelin-1
  • Free Radical Scavengers
  • RNA, Messenger
  • Receptor, Endothelin A
  • Receptor, Endothelin B
  • Superoxides
  • Nitric Oxide
  • Nitric Oxide Synthase Type III
  • Nos3 protein, rat
  • Superoxide Dismutase
  • Acetylcholine
  • NG-Nitroarginine Methyl Ester
  • Indomethacin